← Leaderboards
Michael D Robek
Scripps Research Institute
$7,228,093
Attributed
$7,228,093
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $890.3K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,228,093 · 10
By mechanism
R01$5,583,232 · 3
R21$1,204,861 · 3
K22$268,000 · 1
F32$118,000 · 1
R13$54,000 · 2
Top collaborators
No co-investigators on record.
Most similar at Scripps Research Institute
Same institution · by research overlap
- Francis Vincent Chisari$28,451,545
- Ruben A. Abagyan$7,634,691
- Luca G. Guidotti$5,185,864
- Claire Frances Evans$3,331,612
Others in their field
Top investigators on “Cytokine”
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$83,965,880
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- Fulton T Crews · University Of North Carolina Chapel Hill$36,249,590
- Marianne Ward · Duke University$34,872,957
- Joren C Madsen · Massachusetts General Hospital$33,058,731
- Barton F Haynes · Duke University$29,068,807
Research focus
CytokineVirusMouse ModelImmune ResponseT-LymphocyteVirus ReplicationHepatitis B VirusLiverChronic Hepatitis BInfectionPrimary Carcinoma Of The Liver CellsHepatocyteCessation Of LifeTherapeutic VaccineT Cell ResponseImmunizationViralTransgenic MiceVirus DiseasesViral AntigensResponseProductionVectorBase
Grant awards (31)
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection$491,566
R01 · FY2024 · AI · contact PI
Upstate New York Immunology Conference$8,500
R13 · FY2024 · AI · contact PI
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection$491,566
R01 · FY2023 · AI · contact PI
Upstate New York Immunology Conference$10,500
R13 · FY2023 · AI · contact PI
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection$491,566
R01 · FY2022 · AI · contact PI
Upstate New York Immunology Conference$15,000
R13 · FY2022 · AI · contact PI
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection$491,566
R01 · FY2021 · AI · contact PI
Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection$490,561
R01 · FY2020 · AI · contact PI
Highly Attenuated Vesiculovirus-based Vectors as HBV Therapeutic Vaccines$399,750
R01 · FY2020 · AI · contact PI
Highly Attenuated Vesiculovirus-based Vectors as HBV Therapeutic Vaccines$399,750
R01 · FY2019 · AI · contact PI
Highly Attenuated Vesiculovirus-based Vectors as HBV Therapeutic Vaccines$399,750
R01 · FY2018 · AI · contact PI
Highly Attenuated Vesiculovirus-based Vectors as HBV Therapeutic Vaccines$399,750
R01 · FY2017 · AI · contact PI
Highly Attenuated Vesiculovirus-based Vectors as HBV Therapeutic Vaccines$414,042
R01 · FY2016 · AI · contact PI
A NEW HUMANIZED MOUSE MODEL OF CHRONIC HEPATITIS B$221,664
R21 · FY2015 · AI · contact PI
ENHANCING ONCOLYTIC VIROTHERAPY WITH TYPE III INTERFERON$171,825
R21 · FY2015 · CA · contact PI
Enhancing Oncolytic Virotherapy with Type III Interferon$211,431
R21 · FY2014 · CA · contact PI
A new humanized mouse model of chronic hepatitis B$206,767
R21 · FY2014 · AI · contact PI
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma$229,117
R01 · FY2011 · CA · contact PI
2011 International Meeting on the Molecular Biology of Hepatitis B Viruses$20,000
R13 · FY2011 · AI · contact PI
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma$272,925
R01 · FY2010 · CA · contact PI
IL-22 in HBV pathogenesis$181,666
R21 · FY2010 · CA · contact PI
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma$47,381
R01 · FY2010 · CA · contact PI
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma$267,258
R01 · FY2009 · CA · contact PI
IL-22 in HBV pathogenesis$211,508
R21 · FY2009 · CA · contact PI
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma$21,954
R01 · FY2009 · CA · contact PI
Viral Vaccine Vectors to Prevent Hepatocellular Carcinoma$274,730
R01 · FY2008 · CA · contact PI
Modulation of HBV Replication by the Immunoproteasome$108,000
K22 · FY2006 · AI · contact PI
Modulation of HBV Replication by the Immunoproteasome$160,000
K22 · FY2005 · AI
Molecular Basis of Cytokine-Induced Clearance of HBV DNA$46,420
F32 · FY2003 · AI
Molecular Basis of Cytokine-Induced Clearance of HBV DNA$38,320
F32 · FY2002 · AI
Molecular Basis of Cytokine-Induced Clearance of HBV DNA$33,260
F32 · FY2001 · AI